The Institute of Human Biology (IHB) enables scientists to pioneer human model systems, accelerating the development of new medicines to improve the lives of patients
This follows a $6 million expansion in Rosenberg in 2025 and signals a major push to boost commercial capacity, expand R&D capabilities, and meet rising demand for US-based drug product manufacturing
RSM01, a preventive treatment targeting respiratory syncytial virus (RSV), was licensed earlier this month from the Gates Medical Research Institute
The planned facility, to be built at Samsung’s Bio Campus II, is set to become a launchpad for up to 30 emerging biotech firms
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
The expansion builds on Veristat’s work helping Chinese pharmaceutical firms such as Hansoh Pharma and CStone Pharmaceuticals
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
Cognita CXR leverages a proprietary vision-language model to analyze full chest X-ray studies and generate comprehensive preliminary findings
The conditional, time-limited approval comes through a joint effort with RACTHERA, a joint venture in which Sumitomo Chemical holds a 66.6% stake and Sumitomo Pharma holds 33.4%
Evogene said ChemPass AI was significantly expanded during 2025 through internal development and collaborations with Google Cloud
Subscribe To Our Newsletter & Stay Updated
